We discuss the advantages and disadvantages of using international reference pricing for consistent ...
Read moreWe compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...
Read moreThe pricing dynamics of biosimilars, depends on the type of biosimilar, its indication and the chann...
Read moreAmylyx has set the annual price of the ALS drug to $158,000, whereas ICER have suggested the drug sh...
Read moreIn our research, we determine how consistently IRP is applied in pharmaceutical price re-evaluation ...
Read moreLeem report the changes set out by the Government will heighten the difficulties already being faced...
Read moreIntroduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read moreWe look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read moreThe legislation is an updated, smaller version of The Build Back Better Act (BBBA) which the US Sena...
Read moreThe Haute Autorité de Santé (HAS), recently announced changes to the conditions in which a drug wi...
Read more